Pfizer's Beqvez receives US FDA approval for adults with moderate to severe haemophilia B who currently use FIX ...
Pfizer Inc. announced that the US Food and Drug Administration (FDA) has approved Beqvez (fidanacogene elaparvovec-dzkt) for the treatment of adults with moderate to severe haemophilia B who currently use factor IX (FIX) prophylaxis therapy, or have …